Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

H Strickler

Showing results (81-90 of 100) with videos related to

Pageof 10
Sort By:
Molecular Cancer Research : MCR|March 9, 2016
Development of a Novel c-MET-Based CTC Detection PlatformTian Zhang, Rengasamy Boominathan, Brad Foulk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2022
Treatment of Metastatic Colorectal Cancer: ASCO GuidelineVan K Morris, Erin B Kennedy, Nancy N Baxter, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in <i>KRAS</i> p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
The Lancet. Oncology|December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trialMarwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
BMC Cancer|November 3, 2019
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancerJohn H Strickler, Christel N Rushing, Donna Niedzwiecki, et al.
Journal of Gastroenterology|May 25, 2026
Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancerTaro Shibuki, Celine Hoyek, Ryne Ramaker, et al.
The Lancet. Oncology|May 4, 2023
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H Strickler, Andrea Cercek, Salvatore Siena, et al.
The Oncologist|January 20, 2021
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal CancerJohn H Strickler, Christel N Rushing, Hope E Uronis, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2023
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumorsJohanna Bendell, Patricia LoRusso, Michael Overman, et al.
European Heart Journal|December 6, 2015
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndromeMatthew T Roe, Derek D Cyr, Debra Eckart, et al.
Pageof 10

Showing results (81-90 of 100) with videos related to

Sort By:
Pageof 10
Molecular Cancer Research : MCR|March 9, 2016
Development of a Novel c-MET-Based CTC Detection PlatformTian Zhang, Rengasamy Boominathan, Brad Foulk, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|October 17, 2022
Treatment of Metastatic Colorectal Cancer: ASCO GuidelineVan K Morris, Erin B Kennedy, Nancy N Baxter, et al.
The New England Journal of Medicine|December 22, 2022
Sotorasib in <i>KRAS</i> p.G12C-Mutated Advanced Pancreatic CancerJohn H Strickler, Hironaga Satake, Thomas J George, et al.
The Lancet. Oncology|December 17, 2021
Sotorasib for previously treated colorectal cancers with KRAS<sup>G12C</sup> mutation (CodeBreaK100): a prespecified analysis of a single-arm, phase 2 trialMarwan G Fakih, Scott Kopetz, Yasutoshi Kuboki, et al.
BMC Cancer|November 3, 2019
A phase Ib study of capecitabine and ziv-aflibercept followed by a phase II single-arm expansion cohort in chemotherapy refractory metastatic colorectal cancerJohn H Strickler, Christel N Rushing, Donna Niedzwiecki, et al.
Journal of Gastroenterology|May 25, 2026
Clinico-molecular characteristics and enhanced efficacy of immune checkpoint inhibitors in TP53-mutated advanced biliary tract cancerTaro Shibuki, Celine Hoyek, Ryne Ramaker, et al.
The Lancet. Oncology|May 4, 2023
Tucatinib plus trastuzumab for chemotherapy-refractory, HER2-positive, RAS wild-type unresectable or metastatic colorectal cancer (MOUNTAINEER): a multicentre, open-label, phase 2 studyJohn H Strickler, Andrea Cercek, Salvatore Siena, et al.
The Oncologist|January 20, 2021
Cabozantinib and Panitumumab for RAS Wild-Type Metastatic Colorectal CancerJohn H Strickler, Christel N Rushing, Hope E Uronis, et al.
Cancer Immunology, Immunotherapy : CII|April 4, 2023
First-in-human study of oleclumab, a potent, selective anti-CD73 monoclonal antibody, alone or in combination with durvalumab in patients with advanced solid tumorsJohanna Bendell, Patricia LoRusso, Michael Overman, et al.
European Heart Journal|December 6, 2015
Ascertainment, classification, and impact of neoplasm detection during prolonged treatment with dual antiplatelet therapy with prasugrel vs. clopidogrel following acute coronary syndromeMatthew T Roe, Derek D Cyr, Debra Eckart, et al.
Pageof 10